Inflammatory dermatopathology patterns

Meet the patient — a slide that will not name itself

A 55-year-old has an itchy, bilateral, treatment-resistant eruption on the ankles and feet that has been called "eczema" for a year and has only worsened on topical steroids. The biopsy comes back "chronic spongiotic dermatitis". The pattern is honest; the name is not. The question is not what disease the slide shows but what you failed to put on the request form — and what stain you forgot to order.[1][3]

Hold the two questions that govern inflammatory dermatopathology: what is the dominant pattern at scanning power? and what clinical information and special studies did you plan before the punch hit skin? Pattern naming plus clinicopathologic correlation is the whole game; a biopsy read in isolation is a coin flip.[1]

The Ackerman method — name the pattern, not the disease

Inflammatory dermatopathology interprets non-neoplastic skin disease by reaction pattern rather than by guessing a clinical name from a single microscopic clue. Ackerman's algorithmic method — scan at low power for the dominant pattern, then refine with infiltrate composition, epidermal change, and special studies — is still the teaching backbone decades later.[1][2]

The method exists because pattern and disease are many-to-many. Many diseases share one pattern — spongiosis covers eczema, dermatophyte, drug, and pityriasis rosea. And one disease evolves through patterns over time — acute spongiosis becomes chronic psoriasiform eczema. Clinicopathologic correlation is therefore mandatory, not optional: the report is only as good as the clinical detail on the form.[3][4]

The pattern map — eight buckets, each with its prototypes

Memorise the eight patterns and a prototype disease for each — the table an examiner expects you to reproduce:[1]

[1]

Biopsy strategy — technique decides whether the pathologist can help you

The single biggest determinant of a useful inflammatory report is the specimen you send. A shaved panniculitis, a DIF taken from an ulcer base, or a biopsy of a burned-out plaque centre all guarantee a non-diagnostic report — and the fault is the clinician's, not the pathologist's.[6][7]

[1]

Always write on the form: duration, distribution, drugs, immunosuppression, the differential, and whether infection is possible. Half of a good inflammatory report is written in the clinic.[1]

[3]

The reading order — work the slide like a habit

Read every inflammatory slide in the same order, every time. The board habit:[1]

[1]

Spongiotic — always exclude the dermatophyte

Acute spongiosis shows marked intercellular oedema, lymphocyte exocytosis, and papillary dermal oedema; subacute has less oedema and early acanthosis; chronic spongiosis becomes psoriasiform hyperplasia with residual spongiosis — overlapping psoriasis both clinically and histologically.[1]

The spongiotic pattern is the commonest and the most over-called. Before settling on "eczema", exclude three things every time: dermatophyte (PAS), a contactant or drug in the history, and scabies if the eruption is acral or shows burrows. Paediatric spongiotic disease carries a broader infectious and atopic context — the differential widens with age.[3][4]

Psoriasiform — do not overcall mycosis fungoides on one biopsy

Classic psoriasis shows regular acanthosis, thinned suprapapillary plates, dilated tortuous papillary vessels, Munro microabscesses and spongiform pustules of Kogoj, and confluent parakeratosis with a diminished granular layer. Partial treatment and rubbing distort the picture, so correlate clinically.[1]

The differential of psoriasiform hyperplasia is chronic spongiotic dermatitis, pityriasis rubra pilaris, secondary syphilis (always special stains and serology when it fits), and early mycosis fungoides. MF requires multiple biopsies plus immunophenotyping over time — never call it on one mildly atypical spongiotic specimen. Overcalling lymphoma on early spongiosis is a recurring and damaging error.[1]

Interface and lichenoid — vacuolar versus band-like

The interface family splits into two patterns that point to different diseases. Vacuolar interface change — basal keratinocyte damage, apoptotic Civatte-type bodies, pigment incontinence — is classic for cutaneous lupus and many drug or viral exanthems; CLE histology pairs with the clinical subtype (ACLE, SCLE, DLE) and often shows dermal mucin in DLE.[5]

Band-like lichenoid change — a dense lymphocytic infiltrate hugging the dermoepidermal junction with saw-tooth rete — is the prototype of lichen planus. The lichenoid drug eruption and lichenoid graft-versus-host disease enter the differential, and the drug chart and transplant history are decisive.[10][11][12]

The EM or SJS-TEN spectrum shows interface damage with conspicuous necrotic keratinocytes, often out of proportion to a sparse infiltrate — and clinical severity staging drives management far more than a fancy histologic subtype name. Widespread dusky macules, mucosal erosions, or skin pain with interface necrosis is a severe cutaneous adverse reaction pathway (stop culprit drugs, burn-unit criteria, ophthalmology) — do not wait for a perfect DIF.[1]

Bullous — the split level plus DIF is the diagnosis

For blistering disease the cleft level on H and E and the DIF pattern together make the diagnosis; either alone is insufficient. Memorise the teaching pairs:[1]

[1]

Pemphigus biology and diagnosis rest on clinic, histopathology, DIF, and autoantibody tests as complementary pillars — none of them stands alone, which is why the request form must plan the DIF before the biopsy is taken.[8][9]

Vasculopathic — true vasculitis needs vessel-wall damage

Leukocytoclastic vasculitis is defined by neutrophilic infiltration of post-capillary venules, fibrinoid necrosis of the vessel walls, leukocytoclasia (nuclear dust), and extravasated erythrocytes — in the right clinical setting of palpable purpura. Not every perivascular lymphocyte collection is vasculitis; true vasculitis needs vessel-wall damage, not just cells near a vessel.[1]

The classic trap: calling every perivascular infiltrate "vasculitis". Once LCV is confirmed, the work-up looks for the trigger — drugs, infection, autoimmune serologies, urinalysis, and when indicated ANCA and cryoglobulins.[1]

Granulomatous, folliculitic, panniculitic — and why fat matters

Granulomatous disease sorts by shape: sarcoidal naked granulomas, tuberculoid, palisading (granuloma annulare, necrobiosis lipoidica), and suppurative (infection, follicle rupture). Culture and special stains come before a pure "idiopathic" label, especially in the immunocompromised host.[3]

Folliculitis shows neutrophils in the follicle ± Demodex or bacteria; eosinophilic folliculitis appears in HIV and other contexts. Panniculitis splits into septal (erythema nodosum prototype) versus lobular (lupus panniculitis, pancreatic, infection) — and the diagnosis is impossible without fat in the specimen, which is why a superficial shave cannot answer the question.[6]

Special stains and ancillary tests — a high-yield menu

[1]

From slide to action — the report that changes management

A good inflammatory report states the pattern, gives a favoured diagnosis with two mimics, notes its limits (partial treatment, age of lesion), suggests DIF or PAS if not done, and uses plain language for action. A weak report says only "chronic dermatitis", does not correlate with the clinic, misses PAS on a foot or hand, calls MF on a first mild biopsy, or sends no fat for a panniculitis.[1]

The report-to-management map is what the clinician actually uses. A PAS-negative spongiotic dermatitis sends you down the eczema pathway and back to the contact or drug history; spongiosis plus fungus stops the steroid and starts an antifungal; a lichenoid pattern consistent with lichen planus opens the LP guideline pathway (check drugs and hepatitis C context as indicated).[10][11] Interface necrosis with an EM-like picture pulls the drug chart and severity staging; LCV triggers the systemic screen; a subepidermal blister with linear IgG on DIF is the bullous pemphigoid work-up.[1]

Special populations — and the pitfalls that fail candidates

Children show more infectious, atopic, and genodermatosis patterns; sampling and the differential differ from adult boards.[4] Pregnancy is where DIF distinguishes pemphigoid gestationis from polymorphic eruption when blisters confuse. The elderly raise the BP-versus-scabies-versus-drug question — and eosinophils do not equal BP without the full picture. The immunosuppressed are "infection until proven otherwise" in granulomatous or neutrophilic patterns.[3]

The recurring pitfalls every candidate must name: biopsying the treated or burned-out centre of a plaque; calling every perivascular infiltrate "vasculitis"; missing fungus, scabies, or herpes in "inflammatory" skin; overcalling mycosis fungoides on an early spongiotic dermatitis; sending no fat in a panniculitis work-up; and taking DIF from a necrotic centre instead of perilesional skin.[8][9]

The mnemonic, and the viva honesty line

[1]

The viva honesty line: "I read the slide by pattern at scanning power, work through epidermis, junction, dermis, and fat in order, plan PAS and DIF before I biopsy, exclude infection before settling on a sterile diagnosis, and write a clinicopathologic correlation rather than a guess. Ackerman pattern analysis is the operating system."[1][2]

Ward-round test — three stems, thirty seconds each

Stem 1 — the steroid-treated foot eczema (answer)

A 55-year-old has a unilateral, treatment-resistant spongiotic eruption on one foot that has worsened on a topical steroid for a year. The biopsy reads "chronic spongiotic dermatitis". What was missed, and what do you do now? Model: The pattern is honest; the work-up was incomplete. A spongiotic foot or hand that is not responding is dermatophyte until proven otherwise, and the missed test is PAS (or GMS) — the classic steroid-treated tinea that hides on H and E alone. Order PAS on the block (or re-biopsy), check the nails and contralateral foot as a reservoir, stop the lone steroid, and treat with an antifungal if hyphae are confirmed. The lesson is to plan the stain before the biopsy.[3]

Stem 2 — the tense bullae in an elderly patient (answer)

An 80-year-old has tense bullae and urticarial plaques. What is the diagnostic combination, and what was the specimen error if only an ulcer base was sent for DIF? Model: The combination is cleft level on H and E plus DIF pattern. Bullous pemphigoid — the likely diagnosis — shows a subepidermal blister with an intact roof and eosinophils, and linear IgG and C3 along the basement membrane zone on DIF. The error is sending the ulcer base for DIF: DIF must be taken from perilesional skin (Michel or saline medium per lab), because the ulcer base is necrotic and non-diagnostic. Salt-split refines pemphigoid from epidermolysis bullosa acquisita.[1]

Stem 3 — the atypical lymphoid infiltrate on a first biopsy (answer)

A registrar calls you, excited: a mildly atypical spongiotic specimen "looks like mycosis fungoides" and they plan to start work-up. What is the right response? Model: Slow down — do not call mycosis fungoides on one mildly atypical spongiotic specimen. MF requires multiple biopsies plus immunophenotyping (CD3, CD4, CD8, CD30) demonstrated over time, with clinicopathologic correlation. Treat the eruption clinically, re-biopsy if it evolves, and reserve IHC for when lymphoma is genuinely in the sustained differential. Overcalling lymphoma on early spongiosis is a recurring and damaging error.[1]

References

1. [1]Ackerman AB. An algorithmic method for histologic diagnosis of inflammatory and neoplastic skin diseases by analysis of their patterns Am J Dermatopathol, 1985.PMID 4025726
2. [2]Paredes BE. [Pattern analysis of inflammatory skin diseases according to A. B. Ackerman-always up to date] Pathologe, 2020.PMID 32377832
3. [3]Smith EH, Chan MP. Inflammatory Dermatopathology for General Surgical Pathologists Clin Lab Med, 2017.PMID 28802506
4. [4]Hsi AC, Rosman IS. Histopathology of Cutaneous Inflammatory Disorders in Children Pediatr Dev Pathol, 2018.PMID 29607753
5. [5]Fetter T, Braegelmann C, de Vos L, et al. Current Concepts on Pathogenic Mechanisms and Histopathology in Cutaneous Lupus Erythematosus Front Med (Lausanne), 2022.PMID 35712102
6. [6]Greenwood JD, Merry SP, Boswell CL. Skin Biopsy Techniques Prim Care, 2022.PMID 35125151
7. [7]Pickett H. Shave and punch biopsy for skin lesions Am Fam Physician, 2011.PMID 22046939
8. [8]Schmidt E, Kasperkiewicz M, Joly P. Pemphigus Lancet, 2019.PMID 31498102
9. [9]Kasperkiewicz M, Ellebrecht CT, Takahashi H, et al. Pemphigus Nat Rev Dis Primers, 2017.PMID 28492232
10. [10]Ioannides D, Vakirlis E, Kemeny L, et al. European S1 guidelines on the management of lichen planus: a cooperation of the European Dermatology Forum with the European Academy of Dermatology and Venereology J Eur Acad Dermatol Venereol, 2020.PMID 32678513
11. [11]Le Cleach L, Chosidow O. Clinical practice. Lichen planus N Engl J Med, 2012.PMID 22356325
12. [12]Atzmony L, Reiter O, Hodak E, et al. Treatments for Cutaneous Lichen Planus: A Systematic Review and Meta-Analysis Am J Clin Dermatol, 2016.PMID 26507510